Search
Search
John P. Fezza, MD
Show Description +
Over 16 million people have been diagnosed with dry eye disease (DED) in the United States. In this video, John P. Fezza, MD, highlights LACRIFILL® Canalicular Gel (Nordic Pharma, Inc. ™) as a game changer for how he views dry eye in his practice. Learn more about this cross-linked hyaluronic acid and the in-office procedure.
Posted: 9/06/2024
John P. Fezza, MD
Over 16 million people have been diagnosed with dry eye disease (DED) in the United States. In this video, John P. Fezza, MD, highlights LACRIFILL® Canalicular Gel (Nordic Pharma, Inc. ™) as a game changer for how he views dry eye in his practice. Learn more about this cross-linked hyaluronic acid and the in-office procedure.
Posted: 9/06/2024
LACRIFILL® and Reimbursement
LACRIFILL® Instructions for Use
LACRIFILL® Canalicular Gel Detail Aid
About Nordic Pharma
Nordic Pharma, Inc., subsidiary of Nordic Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
Visit us online: nordicpharmausa.com
Dr. Brandon Ayres, Kevin Corcoran, Dr. Neel Desai, and Dr. John Fezza are paid consultants of Nordic Pharma, Inc.
Contraindications
LACRIFILL is contraindicated for patients experiencing epiphora, inflammation of the eye lid, and tearing secondary to dacryocystitis with mucopurulent discharge and any other active ocular or periocular infection, those who are allergic to hyaluronic acid or to the specific device material, and those who have known lacrimal outflow obstruction.
Rx Only
The Nordic Pharma Logo is a trademark of Nordic Group B.V.
Nordic Pharma, Inc. / 1205 Westlakes Dr., Suite 275, Berwyn, PA 19312
844.304.4828 / www.nordicpharmausa.com • © 2024 Nordic Pharma, Inc.
062024309 • PM24-010-2V5
LACRIFILL® is a registered trademark of Nordic Pharma, Inc.
U.S. Pat. Nos. 8,979,821 and 9,504,605.
